What up with that TWEET?
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
As much as all here would love to see a license from Gilead, one must realize Gilead makes billions off of HIV products. Their older drugs were toxic to bone and kidneys and their newer ones aren't much better.
Putting aside remdesivir, the Gilead story right now is one focused on change. The company, which shot to pharmaceutical prominence in 2013 with the Food and Drug Administration approval of the hepatitis-C cure Sovaldi, has lately turned its gaze on oncology. (That’s the thing about developing a cure; at its peak, Sovaldi brought in $10 billion in 2014, but demand fell off as fewer people were in need of treatment.)
Since the beginning of March, the drugmaker has signed two cancer-focused deals: an acquisition of immuno-oncology company Forty Seven Inc. for $4.9 billion, and a three-year research collaboration with Onko-innate in which the biotech received an undisclosed upfront payment. There have also been recent reports that Gilead is considering a stake in Arcus Biosciences Inc., another cancer therapy developer.
The company’s well-known HIV drug portfolio, which made up 74% of total sales last year, got a boost with the 2018 approval of Biktarvy, which brought in $4.7 billion in 2019, up from $1.9 billion in 2018. The drug is on track for $6.8 billion in sales this year, according to a FactSet consensus. And while some analysts have raised questions about how shelter-in-place orders will impact prescription drug sales, “for the most part growth brands are still growing (Biktarvy, Dupixent, Aimovig),” Bernstein analysts wrote on Monday.
ENZC is an answer to Gilead toxicity problems and they can continue to make billions except they would have to share some of those billions with us.
If not Gilead someone will help bring ENZC products to the market.
It appears to be a when not if situation.
